Artiva Biotherapeutics, Inc. - 8-K Filing
Artiva Biotherapeutics reported Q1 2026 financial results and announced positive initial clinical data for AlloNK in combination with rituximab. The company suspended its at-the-market equity offering under the Sales Agreement with Leerink Partners LLC pending a new prospectus supplement, while also disclosing alignment with the FDA on a Phase 3 trial design for refractory rheumatoid arthritis (RA). (Items: 2.02 Results of Operations and Financial Condition, 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $ARTV